Endothelium: a new target for cardiovascular therapeutics∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
- 1 January 2000
- journal article
- editorial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 35 (1) , 67-70
- https://doi.org/10.1016/s0735-1097(99)00536-7
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- The Discovery of Endothelium-Derived Relaxing Factor and Its Importance in the Identification of Nitric OxideJAMA, 1996
- Angiotensin-Converting Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor Dysfunction in Patients With Coronary Artery DiseaseCirculation, 1996
- Close relation of endothelial function in the human coronary and peripheral circulationsJournal of the American College of Cardiology, 1995
- Endothelium-Dependent Effects of Converting-Enzyme InhibitorsJournal of Cardiovascular Pharmacology, 1993
- Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosisThe Lancet, 1992
- Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease.Circulation, 1990
- ANGIOTENSIN CONVERTING ENZYME IN THE RAT HEART: STUDIES OF ITS INHIBITION IN VITRO AND EX VIVOClinical and Experimental Pharmacology and Physiology, 1989
- Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.Proceedings of the National Academy of Sciences, 1987
- Role of endothelial cells in relaxation of isolated arteries by bradykinin.Proceedings of the National Academy of Sciences, 1982
- The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature, 1980